Leshem B, Epstein E, Kedar E
Lautenberg Center for General and Tumor Immunology, Hebrew University-Hadassah Medical School, Jerusalem, Israel.
Immunol Lett. 1989 Jan 15;20(1):53-8. doi: 10.1016/0165-2478(89)90068-0.
We have previously demonstrated that high frequency (1/20) of potent cytotoxic cells reactive with the nonimmunogenic lymphoma PIR-2 of C57BL/6 (B6, H-2b) origin, can be obtained by allosensitization of syngeneic B6 splenocytes against BALB/c (H-2d) splenocytes in limiting dilution cultures (LDC). Since a high concentration (250 U/ml) of exogenous interleukin 2 (IL-2), sufficient for the elicitation of lymphokine-activated killer (LAK) cells, was used in the LDC, and because the LDC-derived cytotoxic cells were active against a wide spectrum of target cells, we investigated whether the anti PIR-2 effector cells are LAK cells or cytotoxic T lymphocytes (CTL). We found that depletion from the B6 responder cell population of Lyt2+ (CTL precursors), but not of asialo GM1+ (LAK cell precursors), prior to LDC, results in the ablation of anti PIR-2 activity. When B6 splenocytes were plated in LDC with IL-2, in the absence of allogeneic stimulating cells, the resulting anti PIR-2 activity was greater than 10- to 500-fold lower than that obtained in LDC in the presence of allogeneic stimulating cells and IL-2. These and other observations suggest that the cytotoxic response against syngeneic tumors elicited by alloantigens in LDC is mediated by CTL rather than LAK cells, and that allogeneic sensitization in LDC can provide a means for the generation of CTL against syngeneic, nonimmunogenic tumors.
我们之前已经证明,通过在有限稀释培养(LDC)中用同基因的B6脾细胞对BALB/c(H-2d)脾细胞进行同种致敏,可以获得高频(1/20)的、能与C57BL/6(B6,H-2b)来源的非免疫原性淋巴瘤PIR-2发生反应的高效细胞毒性细胞。由于在LDC中使用了高浓度(250 U/ml)的外源性白细胞介素2(IL-2),其足以诱导淋巴因子激活的杀伤细胞(LAK细胞),并且由于LDC来源的细胞毒性细胞对广泛的靶细胞具有活性,我们研究了抗PIR-2效应细胞是LAK细胞还是细胞毒性T淋巴细胞(CTL)。我们发现,在LDC之前,从B6反应细胞群体中去除Lyt2 +(CTL前体),而不是去唾液酸GM1 +(LAK细胞前体),会导致抗PIR-2活性的丧失。当在没有同种异体刺激细胞的情况下,将B6脾细胞接种到含有IL-2的LDC中时,产生的抗PIR-2活性比在存在同种异体刺激细胞和IL-2的LDC中获得的活性低10至500倍以上。这些以及其他观察结果表明,LDC中同种异体抗原引发的针对同基因肿瘤的细胞毒性反应是由CTL介导的,而不是由LAK细胞介导的,并且LDC中的同种异体致敏可以提供一种产生针对同基因、非免疫原性肿瘤的CTL的方法。